Literature DB >> 3171177

Differential recognition of Leishmania aethiopica antigens by lymphocytes from patients with local and diffuse cutaneous leishmaniasis. Evidence for antigen-induced immune suppression.

H O Akuffo1, T E Fehniger, S Britton.   

Abstract

Data are presented to suggest that differential Ag expression by parasites derived from diffuse (DCL) vs local (LCL) cutaneous leishmaniasis patients may be responsible for the Ag-specific anergy seen in DCL patients. The evidence suggests that promastigotes derived from DCL patients express epitopes which preferentially stimulate suppressor activities in DCL patients. These determinants appear to be expressed less, if at all by promastigotes derived from LCL patients. The Ag-specific suppression or nonresponsiveness which dominates the immune response in DCL patients during an active infection can be abrogated by drug treatment or removal of live DCL parasites, which suggests that Ag-induced regulatory cells, probably of T cell lineage, are most likely responsible for the nonresponsiveness seen in untreated DCL patients. Thus the mechanisms of immune regulation operating in this disease differ from that of lepromatous leprosy where the specific unresponsiveness (anergy) is irreversible even after successful treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3171177

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Immune reactivity to fractionated Leishmania aethiopica antigens during coinfection with human immunodeficiency virus type 1.

Authors:  S C Arya
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

2.  Indications of the protective role of natural killer cells in human cutaneous leishmaniasis in an area of endemicity.

Authors:  K Maasho; F Sanchez; E Schurr; A Hailu; H Akuffo
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

3.  Natural killer cells in cross-regulation of IL-12 by IL-10 in Leishmania antigen-stimulated blood donor cells.

Authors:  H Akuffo; A Alexis; L Eidsmo; A Saed; S Nylén; K Maasho
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

4.  Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.

Authors:  Geremew Tasew; Susanne Nylén; Thorsten Lieke; Befekadu Lemu; Hailu Meless; Nicolas Ruffin; Dawit Wolday; Abraham Asseffa; Hideo Yagita; Sven Britton; Hannah Akuffo; Francesca Chiodi; Liv Eidsmo
Journal:  PLoS Negl Trop Dis       Date:  2010-10-12

5.  Immune reactivity to fractionated Leishmania aethiopica antigens during active human infection.

Authors:  T Laskay; H G Mariam; T Y Berhane; T E Fehniger; R Kiessling
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

6.  Contribution of non-Leishmania-specific immunity to resistance to Leishmania infection in humans.

Authors:  H O Akuffo; S F Britton
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

7.  Natural and acquired resistance to Leishmania: cellular activation by Leishmania aethiopica of mononuclear cells from unexposed individuals is through the stimulation of natural killer (NK) cells.

Authors:  H Akuffo; K Maasho; R Howe
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

8.  The Genetic Relationship between Leishmania aethiopica and Leishmania tropica Revealed by Comparing Microsatellite Profiles.

Authors:  Lena Krayter; Lionel F Schnur; Gabriele Schönian
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

9.  Resolvin D1 drives establishment of Leishmania amazonensis infection.

Authors:  Hayna Malta-Santos; Bruno B Andrade; Dalila L Zanette; Jackson M Costa; Patrícia T Bozza; Christianne Bandeira-Melo; Aldina Barral; Jaqueline França-Costa; Valéria M Borges
Journal:  Sci Rep       Date:  2017-04-10       Impact factor: 4.379

Review 10.  Cutaneous Leishmaniasis Due to Leishmania aethiopica.

Authors:  Saskia van Henten; Wim Adriaensen; Helina Fikre; Hannah Akuffo; Ermias Diro; Asrat Hailu; Gert Van der Auwera; Johan van Griensven
Journal:  EClinicalMedicine       Date:  2019-01-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.